Q2 Highlights
Revenue of $1,074 million, up 3% on an underlying basis
Trading profit of $232 million, with trading profit margin of 21.6% in-line with expectations
EPSA was 18.0¢ (2012: 17.9¢)
Advanced Wound Management strongly outperformed the market, driven by Bioactives and NPWT
Advanced Surgical Devices delivered a good quarter in Sports Medicine Joint Repair
Continued strong double digit growth in the Emerging and International Markets, with an acquisition underway in Turkey to further strengthen the platform
Interim dividend of 10.4¢ per share, up 5% (2012: 9.9¢)
Share buy-back programme underway with $75 million spent to date
Commenting, Olivier Bohuon, Chief Executive Officer of Smith & Nephew, said:
"The on-going implementation of our Strategic Priorities underpinned our performance in the quarter. We generated stand-out contributions from our areas of focused investment in the Emerging and International Markets and Negative Pressure Wound Therapy. As expected Orthopaedic Reconstruction had a slow quarter and we anticipate a better second half. Our major acquisition, Healthpoint Biotherapeutics, completed an excellent first six months as a Smith & Nephew business.
"Through the share buy-back programme and interim dividend we are delivering enhanced returns to our shareholders today. At the same time we continue to invest in the business, both for organic growth and enhancing our platform through agreed acquisitions in India, Brazil and now in Turkey. We are confident that our actions are reshaping the Group for further success."
